Bard LifeStent and Lutonix DCB for Treatment of Long Lesions in Femoropopliteal Arteries

Completed

• Conditions: Peripheral Artery Disease
• Interventions: Device: Lutonix Drug Coated Balloon

• Registration Number: NCT02278991
• Lead Sponsor: C. R. Bard

Brief Summary

Objective of this study is to evaluate the safety and efficacy of Lutonix 035 Drug Coated Dilatation PTA Catheter with Bard LifeStent Vascular Stent (hereinafter referred to as LifeStent) for treatment of long (10-24 cm) lesions in the SFA and/or proximal popliteal artery.

Detailed Description

The study will observe subjects presenting with claudication or ischemic rest pain (Rutherford category 2-4) and long (10-24 cm in length) native lesions in the infra-inguinal segment (superficial femoral artery \[SFA\] and/or proximal popliteal artery) who are candidates for stenting and pre-/post-dilatation with Drug Coated Balloon (DCB).

Study Timeline

• Study Start: 2014-10
• Study First Submitted: 2014-10-28
• Study First Submitted QC: 2014-10-29
• Study First Posted: 2014-10-30
• Primary Completion: 2017-09
• Study Completion: 2018-10-02
• Status Verified: 2019-10
• Last Update Submitted: 2019-10-07
• Last Update Posted: 2019-10-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 149

Inclusion Criteria

Subjects will be included if all of the following inclusion criteria apply:

1. Age ≥18 years;
2. The subject is legally competent and able to understand the information on the study, has been informed of the nature, the scope and the relevance of the study, voluntarily agrees to participation and the study's provisions, and has duly signed the Informed Consent Form (ICF);
3. Rutherford Category 2-4;
4. Target de novo lesion(s) or non-stented restenotic lesion(s) has angiographic evidence of ≥50% stenosis or occlusion (by visual estimate) and is amenable to treatment with LifeStent® and Lutonix DCB;
5. Patients must be able to be treated with Lutonix DCB and LifeStent®;
6. Total Lutonix DCB treated segment(s) of 10-24 cm in length;
7. Target vessel reference diameter is 4.0-7.0 mm (by visual estimate) and able to be treated with available device size matrix;
8. At least one patent native outflow artery to the ankle free from significant lesion (≥50% stenosis) as confirmed by angiography (treatment of outflow disease is NOT permitted; treatment of in-flow disease is permitted prior to treatment with LifeStent®).
9. No other prior vascular interventions (including contralateral limb) within 2 weeks before and/or planned 30 days after the protocol treatment, with the exception of remote common femoral patch angioplasty separated by at least 2 cm from the target lesion;
10. Female subjects of childbearing potential have a negative urine or serum pregnancy test within 7 days prior to index procedure;
11. Lesion location starts ≥1 cm below the common femoral bifurcation and terminates distally ≤2 cm below the tibial plateau AND ≥1 cm above the origin of the tibioperoneal trunk.

Exclusion Criteria

1. Pregnant, lactating, or planning on becoming pregnant or men intending to father children;
2. Contraindication to Lutonix DCB or LifeStent® per current IFU;
3. Life expectancy of <1 year;
4. Inability to take required antiplatelet/anticoagulant medications per the LifeStent® and Lutonix DCB IFU, or known contraindication (including allergic reaction) or sensitivity to contrast media, nickel, titanium or tantalum that cannot be adequately managed with pre- and post-procedure medication;
5. Intended treatment of outflow disease during the index procedure;
6. Intended use of laser, atherectomy or cryoplasty during index procedure;
7. Sudden symptom onset, acute vessel occlusion, or acute or subacute thrombus in target vessel;
8. History of stroke within 3 months;
9. History of myocardial infarction, thrombolysis or angina within 2 weeks of enrollment;
10. Participation in an investigational drug or another investigational device study until this study's (Lutonix LifeStent® Study) primary endpoint is reached or previous enrollment in this study;
11. Another medical condition, which, in the opinion of the Investigator, may cause the patient to be noncompliant with the CIP or confound data interpretation;
12. Target vessel and/or lesion involves a previously placed stent.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Lutonix Drug Coated Balloon	Lutonix Drug Coated Balloon	Paclitaxel coated balloon catheter

Primary Outcome Measures

Name	Time	Method
Freedom from the composite endpoint of death, index limb amputation, and target vessel revascularization at 30 days.	30 days	Freedom from the composite endpoint of death, index limb amputation, and target vessel revascularization at 30 days.
Primary patency at 12 months.	12 months	Primary patency is defined as the absence of target lesion restenosis and freedom from target lesion revascularization.

Secondary Outcome Measures

Name	Time	Method
All-cause death	30 days, 6, 12 and 24 months	Death by any cause will be counted.
Amputation (above the ankle)-free survival	30 days, 6, 12 and 24 months	Amputations above the ankle of the target leg will be counted.
Freedom from Target Lesion Revascularization after 30 days, and 6, 12 and 24 months post-index procedure.	30 days, 6, 12 and 24 months	Absence of Target Lesion Revascularization.
Change in resting ankle brachial index (ABI) from baseline to 30 days, and 6, 12 and 24 months post-index procedure	30 days, 6, 12 and 24 months	The ABI values will be recorded and compared to the baseline values. The ABI is the ratio of the blood pressure at the ankle to the blood pressure in the upper arm. A ratio of 0.9-1.3 is in the normal range. Lower ratios indicate bad blood perfusion of the leg.
Procedural success	Immediately after Intervention	Defined as attainment of ≤30% residual stenosis by quantitative angiography immediately after intervention in the absence of peri-procedural complications.
Device success	Immediately after intervention	Defined as successful delivery of the DCB to the target lesion and performance when used according to the clinical investigational plan.
Technical success	Immediately after intervention	Defined as attainment of ≤30% residual stenosis by quantitative angiography.
Freedom from TVR after 30 days, and 6, 12 and 24 months post-index procedure.	30 days, 6, 12 and 24 months	Absence of Target Vessel Revascularization.
Change in Rutherford Classification from baseline to 30 days, and 6, 12 and 24 months post-index procedure	30 days, 6, 12 and 24 months	Patients are enrolled with a Rutherford grade of 2-4 for their target leg. The Rutherford scale is an indicator for the severity of Peripheral Vascular Disease: 0 = no symptoms, 6 = functional foot is no longer salvageable (leading to foot amputation).
Target limb reintervention for treatment of thrombosis of target vessel or embolization to its distal vasculature	30 days, 6, 12 and 24 months	Thrombosis in the target vessel and embolizations below the target lesion will be analazed separately from other stenoses.

Trial Locations

Locations (12)

Klinikum Arnsberg; 🇩🇪 Arnsberg, Germany

Herz- und Gefäßzentrum Bad Bevensen; 🇩🇪 Bad Bevensen, Germany

Universitäts-Herzzentrum Freiburg Bad Krozingen; 🇩🇪 Bad Krozingen, Germany

Angiologikum Hamburg; 🇩🇪 Hamburg, Germany

Klinik Immenstadt; 🇩🇪 Immenstadt, Germany

Klinikum Kassel; 🇩🇪 Kassel, Germany

UKSH - Campus Lübeck; 🇩🇪 Lübeck, Germany

RoMed Klinikum Rosenheim; 🇩🇪 Rosenheim, Germany

Klinikum Weiden; 🇩🇪 Weiden, Germany

Gefäßzentrum Sonneberg; 🇩🇪 Sonneberg, Germany

University General Hospital of Patras; 🇬🇷 Patras, Greece

SPZOZ Sanok; 🇵🇱 Sanok, Poland